nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Dactinomycin—muscle cancer	0.135	0.25	CbGbCtD
Afatinib—ABCG2—Vincristine—muscle cancer	0.0833	0.154	CbGbCtD
Afatinib—ABCG2—Etoposide—muscle cancer	0.0763	0.141	CbGbCtD
Afatinib—ABCG2—Doxorubicin—muscle cancer	0.0521	0.0963	CbGbCtD
Afatinib—ABCG2—Methotrexate—muscle cancer	0.0504	0.0933	CbGbCtD
Afatinib—ABCB1—Dactinomycin—muscle cancer	0.0488	0.0902	CbGbCtD
Afatinib—ABCB1—Vincristine—muscle cancer	0.03	0.0556	CbGbCtD
Afatinib—ABCB1—Etoposide—muscle cancer	0.0275	0.0509	CbGbCtD
Afatinib—ABCB1—Doxorubicin—muscle cancer	0.0188	0.0347	CbGbCtD
Afatinib—ABCB1—Methotrexate—muscle cancer	0.0182	0.0336	CbGbCtD
Afatinib—Ventricular dysfunction—Doxorubicin—muscle cancer	0.00527	0.0524	CcSEcCtD
Afatinib—ERBB2—embryo—muscle cancer	0.00474	0.0513	CbGeAlD
Afatinib—ERBB4—embryo—muscle cancer	0.00474	0.0513	CbGeAlD
Afatinib—Vandetanib—VEGFA—muscle cancer	0.0047	1	CrCbGaD
Afatinib—Paronychia—Methotrexate—muscle cancer	0.00405	0.0402	CcSEcCtD
Afatinib—Cheilitis—Dactinomycin—muscle cancer	0.00381	0.0379	CcSEcCtD
Afatinib—ERBB2—smooth muscle tissue—muscle cancer	0.00372	0.0403	CbGeAlD
Afatinib—ERBB2—renal system—muscle cancer	0.00358	0.0388	CbGeAlD
Afatinib—DYRK1A—renal system—muscle cancer	0.00345	0.0374	CbGeAlD
Afatinib—HIPK4—testis—muscle cancer	0.00338	0.0366	CbGeAlD
Afatinib—ERBB4—cardiac atrium—muscle cancer	0.00321	0.0348	CbGeAlD
Afatinib—PHKG2—tendon—muscle cancer	0.00311	0.0337	CbGeAlD
Afatinib—Pulmonary toxicity—Methotrexate—muscle cancer	0.00309	0.0307	CcSEcCtD
Afatinib—ERBB4—tendon—muscle cancer	0.0028	0.0303	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—muscle cancer	0.00279	0.0302	CbGeAlD
Afatinib—EPHA6—head—muscle cancer	0.00277	0.03	CbGeAlD
Afatinib—EPHA6—testis—muscle cancer	0.00267	0.0289	CbGeAlD
Afatinib—PHKG2—head—muscle cancer	0.00267	0.0289	CbGeAlD
Afatinib—ERBB4—vagina—muscle cancer	0.0026	0.0281	CbGeAlD
Afatinib—PHKG2—testis—muscle cancer	0.00258	0.0279	CbGeAlD
Afatinib—ERBB2—head—muscle cancer	0.0024	0.026	CbGeAlD
Afatinib—ERBB4—head—muscle cancer	0.0024	0.026	CbGeAlD
Afatinib—ERBB2—testis—muscle cancer	0.00232	0.0251	CbGeAlD
Afatinib—ERBB4—testis—muscle cancer	0.00232	0.0251	CbGeAlD
Afatinib—DYRK1A—head—muscle cancer	0.00231	0.025	CbGeAlD
Afatinib—DYRK1A—testis—muscle cancer	0.00223	0.0242	CbGeAlD
Afatinib—Mucosal inflammation—Etoposide—muscle cancer	0.00212	0.021	CcSEcCtD
Afatinib—IRAK1—tendon—muscle cancer	0.00209	0.0227	CbGeAlD
Afatinib—IRAK1—bone marrow—muscle cancer	0.00203	0.022	CbGeAlD
Afatinib—ERBB2—Podofilox—Etoposide—muscle cancer	0.002	0.225	CbGdCrCtD
Afatinib—ABL1—embryo—muscle cancer	0.00198	0.0215	CbGeAlD
Afatinib—LCK—bone marrow—muscle cancer	0.00198	0.0214	CbGeAlD
Afatinib—EGFR—testis—muscle cancer	0.00196	0.0213	CbGeAlD
Afatinib—LCK—vagina—muscle cancer	0.00189	0.0205	CbGeAlD
Afatinib—IRAK1—testis—muscle cancer	0.00173	0.0188	CbGeAlD
Afatinib—LCK—testis—muscle cancer	0.00169	0.0183	CbGeAlD
Afatinib—Interstitial lung disease—Etoposide—muscle cancer	0.00166	0.0165	CcSEcCtD
Afatinib—ABL1—smooth muscle tissue—muscle cancer	0.00156	0.0169	CbGeAlD
Afatinib—ABL1—renal system—muscle cancer	0.0015	0.0163	CbGeAlD
Afatinib—Mouth ulceration—Dactinomycin—muscle cancer	0.00146	0.0146	CcSEcCtD
Afatinib—Sepsis—Dactinomycin—muscle cancer	0.0014	0.014	CcSEcCtD
Afatinib—ABL1—cardiac atrium—muscle cancer	0.00135	0.0146	CbGeAlD
Afatinib—Mouth ulceration—Vincristine—muscle cancer	0.00131	0.013	CcSEcCtD
Afatinib—Aphthous stomatitis—Doxorubicin—muscle cancer	0.0013	0.0129	CcSEcCtD
Afatinib—Mucosal inflammation—Methotrexate—muscle cancer	0.00127	0.0126	CcSEcCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—muscle cancer	0.00125	0.141	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—muscle cancer	0.00125	0.141	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—muscle cancer	0.00125	0.141	CbGdCrCtD
Afatinib—ABL1—tendon—muscle cancer	0.00117	0.0127	CbGeAlD
Afatinib—ABL1—bone marrow—muscle cancer	0.00114	0.0123	CbGeAlD
Afatinib—Mucosal inflammation—Doxorubicin—muscle cancer	0.0011	0.0109	CcSEcCtD
Afatinib—ABL1—vagina—muscle cancer	0.00109	0.0118	CbGeAlD
Afatinib—Mouth ulceration—Etoposide—muscle cancer	0.00106	0.0105	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00106	0.0105	CcSEcCtD
Afatinib—Sepsis—Etoposide—muscle cancer	0.00102	0.0101	CcSEcCtD
Afatinib—ABL1—head—muscle cancer	0.001	0.0109	CbGeAlD
Afatinib—Interstitial lung disease—Methotrexate—muscle cancer	0.000991	0.00986	CcSEcCtD
Afatinib—Dehydration—Vincristine—muscle cancer	0.000976	0.00971	CcSEcCtD
Afatinib—ABL1—testis—muscle cancer	0.000971	0.0105	CbGeAlD
Afatinib—ERBB2—Epirubicin—Doxorubicin—muscle cancer	0.000965	0.109	CbGdCrCtD
Afatinib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000945	0.0094	CcSEcCtD
Afatinib—Keratitis—Doxorubicin—muscle cancer	0.000937	0.00932	CcSEcCtD
Afatinib—Pneumonia—Dactinomycin—muscle cancer	0.000911	0.00906	CcSEcCtD
Afatinib—Stomatitis—Dactinomycin—muscle cancer	0.000883	0.00878	CcSEcCtD
Afatinib—Weight decreased—Vincristine—muscle cancer	0.000821	0.00817	CcSEcCtD
Afatinib—Pneumonia—Vincristine—muscle cancer	0.000814	0.00809	CcSEcCtD
Afatinib—Stomatitis—Vincristine—muscle cancer	0.000789	0.00784	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00075	0.00746	CcSEcCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.00072	0.081	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.00072	0.081	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.00072	0.081	CbGdCrCtD
Afatinib—Alopecia—Dactinomycin—muscle cancer	0.000718	0.00715	CcSEcCtD
Afatinib—Urinary tract disorder—Vincristine—muscle cancer	0.000717	0.00713	CcSEcCtD
Afatinib—ABCG2—bone marrow—muscle cancer	0.000716	0.00776	CbGeAlD
Afatinib—Connective tissue disorder—Vincristine—muscle cancer	0.000714	0.0071	CcSEcCtD
Afatinib—Urethral disorder—Vincristine—muscle cancer	0.000712	0.00708	CcSEcCtD
Afatinib—ABCG2—vagina—muscle cancer	0.000686	0.00743	CbGeAlD
Afatinib—Cystitis noninfective—Methotrexate—muscle cancer	0.000685	0.00682	CcSEcCtD
Afatinib—Cystitis—Methotrexate—muscle cancer	0.000678	0.00674	CcSEcCtD
Afatinib—Pneumonia—Etoposide—muscle cancer	0.000659	0.00656	CcSEcCtD
Afatinib—Infestation—Etoposide—muscle cancer	0.000655	0.00652	CcSEcCtD
Afatinib—Infestation NOS—Etoposide—muscle cancer	0.000655	0.00652	CcSEcCtD
Afatinib—Mediastinal disorder—Vincristine—muscle cancer	0.000655	0.00651	CcSEcCtD
Afatinib—Renal failure—Etoposide—muscle cancer	0.000644	0.00641	CcSEcCtD
Afatinib—Alopecia—Vincristine—muscle cancer	0.000642	0.00638	CcSEcCtD
Afatinib—Stomatitis—Etoposide—muscle cancer	0.000639	0.00635	CcSEcCtD
Afatinib—Mental disorder—Vincristine—muscle cancer	0.000636	0.00633	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—muscle cancer	0.000634	0.00631	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—muscle cancer	0.000634	0.00631	CcSEcCtD
Afatinib—Hepatobiliary disease—Etoposide—muscle cancer	0.00062	0.00617	CcSEcCtD
Afatinib—ABCB1—embryo—muscle cancer	0.000617	0.00668	CbGeAlD
Afatinib—ABCG2—testis—muscle cancer	0.000612	0.00663	CbGeAlD
Afatinib—Back pain—Vincristine—muscle cancer	0.000612	0.00608	CcSEcCtD
Afatinib—Sepsis—Methotrexate—muscle cancer	0.000609	0.00606	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—muscle cancer	0.000594	0.0059	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—muscle cancer	0.000587	0.00584	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—muscle cancer	0.000581	0.00578	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—muscle cancer	0.000577	0.00574	CcSEcCtD
Afatinib—Infection—Dactinomycin—muscle cancer	0.000574	0.00571	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—muscle cancer	0.000561	0.00558	CcSEcCtD
Afatinib—Eye disorder—Etoposide—muscle cancer	0.00055	0.00547	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—muscle cancer	0.000549	0.00547	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—muscle cancer	0.000549	0.00547	CcSEcCtD
Afatinib—Mediastinal disorder—Etoposide—muscle cancer	0.00053	0.00527	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—muscle cancer	0.000527	0.00525	CcSEcCtD
Afatinib—Alopecia—Etoposide—muscle cancer	0.00052	0.00517	CcSEcCtD
Afatinib—Infection—Vincristine—muscle cancer	0.000513	0.0051	CcSEcCtD
Afatinib—Nervous system disorder—Vincristine—muscle cancer	0.000506	0.00503	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—muscle cancer	0.000502	0.00499	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—muscle cancer	0.000502	0.00499	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—muscle cancer	0.000498	0.00495	CcSEcCtD
Afatinib—Back pain—Etoposide—muscle cancer	0.000495	0.00493	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—muscle cancer	0.000492	0.0049	CcSEcCtD
Afatinib—ABCB1—renal system—muscle cancer	0.000467	0.00506	CbGeAlD
Afatinib—Insomnia—Vincristine—muscle cancer	0.000467	0.00464	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—muscle cancer	0.000463	0.00461	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—muscle cancer	0.000457	0.00454	CcSEcCtD
Afatinib—Decreased appetite—Vincristine—muscle cancer	0.000449	0.00446	CcSEcCtD
Afatinib—Cough—Etoposide—muscle cancer	0.000447	0.00445	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000445	0.00443	CcSEcCtD
Afatinib—Fatigue—Vincristine—muscle cancer	0.000445	0.00443	CcSEcCtD
Afatinib—Constipation—Vincristine—muscle cancer	0.000441	0.00439	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000433	0.00431	CcSEcCtD
Afatinib—Infection—Etoposide—muscle cancer	0.000415	0.00413	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—muscle cancer	0.000414	0.00412	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—muscle cancer	0.00041	0.00408	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000409	0.00407	CcSEcCtD
Afatinib—Body temperature increased—Vincristine—muscle cancer	0.000408	0.00406	CcSEcCtD
Afatinib—Skin disorder—Etoposide—muscle cancer	0.000406	0.00404	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—muscle cancer	0.000404	0.00402	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—muscle cancer	0.000401	0.00399	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000397	0.00395	CcSEcCtD
Afatinib—Diarrhoea—Dactinomycin—muscle cancer	0.000395	0.00393	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—muscle cancer	0.000395	0.00393	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—muscle cancer	0.000394	0.00392	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—muscle cancer	0.000393	0.0039	CcSEcCtD
Afatinib—Infestation—Methotrexate—muscle cancer	0.000393	0.0039	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000389	0.00387	CcSEcCtD
Afatinib—Renal failure—Methotrexate—muscle cancer	0.000386	0.00384	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—muscle cancer	0.000383	0.00381	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—muscle cancer	0.000382	0.0038	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—muscle cancer	0.000373	0.00371	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000371	0.00369	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—muscle cancer	0.00037	0.00368	CcSEcCtD
Afatinib—Asthenia—Vincristine—muscle cancer	0.00037	0.00368	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—muscle cancer	0.000367	0.00365	CcSEcCtD
Afatinib—Rash—Dactinomycin—muscle cancer	0.000364	0.00362	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—muscle cancer	0.000363	0.00361	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000361	0.00359	CcSEcCtD
Afatinib—Fatigue—Etoposide—muscle cancer	0.00036	0.00358	CcSEcCtD
Afatinib—Constipation—Etoposide—muscle cancer	0.000357	0.00356	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000354	0.00352	CcSEcCtD
Afatinib—ABCB1—bone marrow—muscle cancer	0.000353	0.00383	CbGeAlD
Afatinib—Diarrhoea—Vincristine—muscle cancer	0.000353	0.00351	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—muscle cancer	0.000348	0.00346	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—muscle cancer	0.000345	0.00344	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—muscle cancer	0.000345	0.00343	CcSEcCtD
Afatinib—Nausea—Dactinomycin—muscle cancer	0.000343	0.00341	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—muscle cancer	0.000342	0.0034	CcSEcCtD
Afatinib—Dizziness—Vincristine—muscle cancer	0.000341	0.00339	CcSEcCtD
Afatinib—Infestation—Doxorubicin—muscle cancer	0.00034	0.00338	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—muscle cancer	0.00034	0.00338	CcSEcCtD
Afatinib—ABCB1—vagina—muscle cancer	0.000338	0.00366	CbGeAlD
Afatinib—Renal failure—Doxorubicin—muscle cancer	0.000334	0.00332	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—muscle cancer	0.000331	0.0033	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—muscle cancer	0.00033	0.00329	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—muscle cancer	0.00033	0.00329	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—muscle cancer	0.00033	0.00329	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—muscle cancer	0.000329	0.00328	CcSEcCtD
Afatinib—Vomiting—Vincristine—muscle cancer	0.000328	0.00326	CcSEcCtD
Afatinib—Rash—Vincristine—muscle cancer	0.000325	0.00324	CcSEcCtD
Afatinib—Dermatitis—Vincristine—muscle cancer	0.000325	0.00323	CcSEcCtD
Afatinib—Headache—Vincristine—muscle cancer	0.000323	0.00322	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000321	0.0032	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—muscle cancer	0.000321	0.00319	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—muscle cancer	0.000318	0.00316	CcSEcCtD
Afatinib—ABCB1—head—muscle cancer	0.000313	0.00339	CbGeAlD
Afatinib—Alopecia—Methotrexate—muscle cancer	0.000311	0.0031	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—muscle cancer	0.000309	0.00307	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—muscle cancer	0.000307	0.00305	CcSEcCtD
Afatinib—Nausea—Vincristine—muscle cancer	0.000306	0.00305	CcSEcCtD
Afatinib—ABCB1—testis—muscle cancer	0.000302	0.00327	CbGeAlD
Afatinib—Urinary tract disorder—Doxorubicin—muscle cancer	0.000301	0.003	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—muscle cancer	0.0003	0.00299	CcSEcCtD
Afatinib—Asthenia—Etoposide—muscle cancer	0.0003	0.00298	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—muscle cancer	0.0003	0.00298	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—muscle cancer	0.000299	0.00298	CcSEcCtD
Afatinib—Back pain—Methotrexate—muscle cancer	0.000297	0.00295	CcSEcCtD
Afatinib—Pruritus—Etoposide—muscle cancer	0.000296	0.00294	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—muscle cancer	0.000286	0.00284	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—muscle cancer	0.000285	0.00284	CcSEcCtD
Afatinib—Dizziness—Etoposide—muscle cancer	0.000276	0.00275	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000275	0.00274	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—muscle cancer	0.00027	0.00268	CcSEcCtD
Afatinib—Cough—Methotrexate—muscle cancer	0.000268	0.00266	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—muscle cancer	0.000267	0.00266	CcSEcCtD
Afatinib—Vomiting—Etoposide—muscle cancer	0.000266	0.00264	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—muscle cancer	0.000266	0.00264	CcSEcCtD
Afatinib—Rash—Etoposide—muscle cancer	0.000264	0.00262	CcSEcCtD
Afatinib—Dermatitis—Etoposide—muscle cancer	0.000263	0.00262	CcSEcCtD
Afatinib—Headache—Etoposide—muscle cancer	0.000262	0.0026	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—muscle cancer	0.00026	0.00259	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000259	0.00258	CcSEcCtD
Afatinib—Back pain—Doxorubicin—muscle cancer	0.000257	0.00256	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—muscle cancer	0.000255	0.00254	CcSEcCtD
Afatinib—Infection—Methotrexate—muscle cancer	0.000249	0.00247	CcSEcCtD
Afatinib—Nausea—Etoposide—muscle cancer	0.000248	0.00247	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—muscle cancer	0.000246	0.00244	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—muscle cancer	0.000243	0.00242	CcSEcCtD
Afatinib—Cough—Doxorubicin—muscle cancer	0.000232	0.00231	CcSEcCtD
Afatinib—Insomnia—Methotrexate—muscle cancer	0.000226	0.00225	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000225	0.00223	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—muscle cancer	0.000223	0.00222	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—muscle cancer	0.00022	0.00219	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—muscle cancer	0.000218	0.00217	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000216	0.00215	CcSEcCtD
Afatinib—Fatigue—Methotrexate—muscle cancer	0.000216	0.00215	CcSEcCtD
Afatinib—Infection—Doxorubicin—muscle cancer	0.000215	0.00214	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—muscle cancer	0.000213	0.00211	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—muscle cancer	0.000211	0.00209	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—muscle cancer	0.000198	0.00197	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—muscle cancer	0.000196	0.00195	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—muscle cancer	0.000193	0.00192	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—muscle cancer	0.000191	0.0019	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—muscle cancer	0.000188	0.00187	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000187	0.00186	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—muscle cancer	0.000187	0.00186	CcSEcCtD
Afatinib—Constipation—Doxorubicin—muscle cancer	0.000185	0.00184	CcSEcCtD
Afatinib—Asthenia—Methotrexate—muscle cancer	0.00018	0.00179	CcSEcCtD
Afatinib—Pruritus—Methotrexate—muscle cancer	0.000177	0.00176	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—muscle cancer	0.000171	0.0017	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—muscle cancer	0.000171	0.0017	CcSEcCtD
Afatinib—Dizziness—Methotrexate—muscle cancer	0.000166	0.00165	CcSEcCtD
Afatinib—Vomiting—Methotrexate—muscle cancer	0.000159	0.00158	CcSEcCtD
Afatinib—Rash—Methotrexate—muscle cancer	0.000158	0.00157	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—muscle cancer	0.000158	0.00157	CcSEcCtD
Afatinib—Headache—Methotrexate—muscle cancer	0.000157	0.00156	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—muscle cancer	0.000156	0.00155	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—muscle cancer	0.000153	0.00153	CcSEcCtD
Afatinib—Nausea—Methotrexate—muscle cancer	0.000149	0.00148	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—muscle cancer	0.000148	0.00148	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—FOXO1—muscle cancer	0.000144	0.00057	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—KIT—muscle cancer	0.000143	0.000567	CbGpPWpGaD
Afatinib—Dizziness—Doxorubicin—muscle cancer	0.000143	0.00143	CcSEcCtD
Afatinib—EGFR—Direct p53 effectors—MDM2—muscle cancer	0.000143	0.000564	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000142	0.000562	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—MDM2—muscle cancer	0.000142	0.000561	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—KIT—muscle cancer	0.000142	0.00056	CbGpPWpGaD
Afatinib—ERBB2—Disease—ENO2—muscle cancer	0.000142	0.00056	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD34—muscle cancer	0.000141	0.000558	CbGpPWpGaD
Afatinib—ABL1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.00014	0.000554	CbGpPWpGaD
Afatinib—ERBB4—Disease—ENO2—muscle cancer	0.000139	0.000551	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—KIT—muscle cancer	0.000139	0.00055	CbGpPWpGaD
Afatinib—Vomiting—Doxorubicin—muscle cancer	0.000138	0.00137	CcSEcCtD
Afatinib—LCK—Signaling by SCF-KIT—MDM2—muscle cancer	0.000137	0.000541	CbGpPWpGaD
Afatinib—Rash—Doxorubicin—muscle cancer	0.000137	0.00136	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—muscle cancer	0.000137	0.00136	CcSEcCtD
Afatinib—Headache—Doxorubicin—muscle cancer	0.000136	0.00135	CcSEcCtD
Afatinib—EGFR—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000136	0.000537	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000134	0.000531	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—FOXO1—muscle cancer	0.000134	0.000531	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—KIT—muscle cancer	0.000134	0.00053	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—MDM2—muscle cancer	0.000134	0.000528	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000133	0.000526	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD34—muscle cancer	0.000133	0.000526	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000132	0.000522	CbGpPWpGaD
Afatinib—PHKG2—Disease—KIT—muscle cancer	0.000131	0.000518	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000131	0.000517	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.00013	0.000515	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—FOXO1—muscle cancer	0.000129	0.000512	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—MDM2—muscle cancer	0.000129	0.000509	CbGpPWpGaD
Afatinib—Nausea—Doxorubicin—muscle cancer	0.000129	0.00128	CcSEcCtD
Afatinib—ERBB2—Disease—HMGA1—muscle cancer	0.000129	0.000509	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000128	0.000507	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—MDM2—muscle cancer	0.000128	0.000505	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—MDM2—muscle cancer	0.000127	0.000502	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000127	0.000501	CbGpPWpGaD
Afatinib—ERBB4—Disease—HMGA1—muscle cancer	0.000127	0.000501	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—MDM2—muscle cancer	0.000126	0.0005	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—MDM2—muscle cancer	0.000126	0.000497	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000126	0.000497	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000126	0.000497	CbGpPWpGaD
Afatinib—ERBB2—Immune System—FOXO4—muscle cancer	0.000125	0.000494	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000124	0.00049	CbGpPWpGaD
Afatinib—ABL1—Cell Cycle—TP53—muscle cancer	0.000123	0.000488	CbGpPWpGaD
Afatinib—ERBB4—Immune System—FOXO4—muscle cancer	0.000123	0.000487	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—MDM2—muscle cancer	0.000123	0.000486	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—MDM2—muscle cancer	0.000122	0.000484	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—MDM2—muscle cancer	0.000122	0.000482	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—FOXO4—muscle cancer	0.000121	0.00048	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—MDM2—muscle cancer	0.000121	0.000479	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—KIT—muscle cancer	0.000121	0.000477	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—MDM2—muscle cancer	0.000121	0.000477	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000119	0.000472	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000119	0.000472	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—KIT—muscle cancer	0.000119	0.00047	CbGpPWpGaD
Afatinib—BLK—Immune System—FOXO4—muscle cancer	0.000118	0.000468	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—MDM2—muscle cancer	0.000118	0.000468	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—MDM2—muscle cancer	0.000118	0.000468	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000118	0.000468	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—MDM2—muscle cancer	0.000117	0.000464	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	0.000117	0.000463	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000116	0.00046	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—KIT—muscle cancer	0.000116	0.000458	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—MDM2—muscle cancer	0.000116	0.000458	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIDINS220—muscle cancer	0.000115	0.000456	CbGpPWpGaD
Afatinib—ERBB2—Disease—FOXO4—muscle cancer	0.000115	0.000456	CbGpPWpGaD
Afatinib—DYRK1A—Cell Cycle—TP53—muscle cancer	0.000115	0.000456	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—VEGFA—muscle cancer	0.000115	0.000453	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—FOXO1—muscle cancer	0.000115	0.000453	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—KIT—muscle cancer	0.000114	0.000452	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000114	0.000451	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—MDM2—muscle cancer	0.000114	0.000451	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—MDM2—muscle cancer	0.000114	0.000451	CbGpPWpGaD
Afatinib—ERBB4—Disease—FOXO4—muscle cancer	0.000114	0.000449	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—MDM2—muscle cancer	0.000113	0.000447	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000112	0.000443	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—MDM2—muscle cancer	0.000112	0.000441	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000111	0.00044	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIDINS220—muscle cancer	0.000111	0.00044	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—VEGFA—muscle cancer	0.00011	0.000437	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—KIT—muscle cancer	0.00011	0.000434	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—MDM2—muscle cancer	0.000109	0.000433	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—IGF2—muscle cancer	0.000108	0.000428	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000107	0.000424	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—MDM2—muscle cancer	0.000106	0.000417	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000105	0.000414	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD34—muscle cancer	0.000104	0.000411	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—FH—muscle cancer	0.000104	0.000411	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FOXO4—muscle cancer	0.000104	0.00041	CbGpPWpGaD
Afatinib—PHKG2—Disease—MDM2—muscle cancer	0.000103	0.000408	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—KIT—muscle cancer	0.000102	0.000405	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000102	0.000403	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—FOXO1—muscle cancer	0.000102	0.000401	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000101	0.000399	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FOXO4—muscle cancer	0.0001	0.000395	CbGpPWpGaD
Afatinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	9.98e-05	0.000395	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FOXO4—muscle cancer	9.96e-05	0.000394	CbGpPWpGaD
Afatinib—PHKG2—Disease—PTGS2—muscle cancer	9.94e-05	0.000393	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	9.89e-05	0.000391	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—KIT—muscle cancer	9.86e-05	0.00039	CbGpPWpGaD
Afatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—muscle cancer	9.81e-05	0.000388	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FOXO4—muscle cancer	9.6e-05	0.00038	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—MDM2—muscle cancer	9.51e-05	0.000376	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTCH1—muscle cancer	9.4e-05	0.000372	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TP53—muscle cancer	9.39e-05	0.000371	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—MDM2—muscle cancer	9.37e-05	0.00037	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTCH1—muscle cancer	9.26e-05	0.000366	CbGpPWpGaD
Afatinib—ERBB2—Immune System—FOXO1—muscle cancer	9.23e-05	0.000365	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—MDM2—muscle cancer	9.13e-05	0.000361	CbGpPWpGaD
Afatinib—ERBB4—Immune System—FOXO1—muscle cancer	9.09e-05	0.000359	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FOXO4—muscle cancer	9.04e-05	0.000357	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—TP53—muscle cancer	9.02e-05	0.000357	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—MDM2—muscle cancer	8.99e-05	0.000356	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—FOXO1—muscle cancer	8.96e-05	0.000354	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IGF2—muscle cancer	8.91e-05	0.000352	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD34—muscle cancer	8.89e-05	0.000351	CbGpPWpGaD
Afatinib—BLK—Immune System—FOXO1—muscle cancer	8.75e-05	0.000346	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KIT—muscle cancer	8.73e-05	0.000345	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—FOXO1—muscle cancer	8.67e-05	0.000343	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—MDM2—muscle cancer	8.65e-05	0.000342	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	8.65e-05	0.000342	CbGpPWpGaD
Afatinib—LCK—Immune System—CD34—muscle cancer	8.57e-05	0.000339	CbGpPWpGaD
Afatinib—ERBB2—Disease—FOXO1—muscle cancer	8.52e-05	0.000337	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—VEGFA—muscle cancer	8.49e-05	0.000336	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.45e-05	0.000334	CbGpPWpGaD
Afatinib—ERBB4—Disease—FOXO1—muscle cancer	8.39e-05	0.000332	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—PTGS2—muscle cancer	8.33e-05	0.000329	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—muscle cancer	8.19e-05	0.000324	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—VEGFA—muscle cancer	8.18e-05	0.000323	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FOXO4—muscle cancer	8.08e-05	0.000319	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—MDM2—muscle cancer	8.06e-05	0.000319	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FOXO4—muscle cancer	7.96e-05	0.000315	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CNR1—muscle cancer	7.93e-05	0.000314	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CNR1—muscle cancer	7.81e-05	0.000309	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—MDM2—muscle cancer	7.77e-05	0.000307	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—muscle cancer	7.71e-05	0.000305	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PTCH1—muscle cancer	7.69e-05	0.000304	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FOXO1—muscle cancer	7.66e-05	0.000303	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	7.48e-05	0.000296	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FOXO1—muscle cancer	7.38e-05	0.000292	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FOXO1—muscle cancer	7.36e-05	0.000291	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	7.25e-05	0.000287	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FOXO1—muscle cancer	7.09e-05	0.00028	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—muscle cancer	7.08e-05	0.00028	CbGpPWpGaD
Afatinib—ABL1—Immune System—FOXO4—muscle cancer	7.07e-05	0.00028	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KIT—muscle cancer	7.03e-05	0.000278	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KIT—muscle cancer	6.93e-05	0.000274	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—MDM2—muscle cancer	6.87e-05	0.000272	CbGpPWpGaD
Afatinib—EGFR—Disease—ENO2—muscle cancer	6.84e-05	0.000271	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KIT—muscle cancer	6.83e-05	0.00027	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTCH1—muscle cancer	6.79e-05	0.000269	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FOXO1—muscle cancer	6.67e-05	0.000264	CbGpPWpGaD
Afatinib—BLK—Immune System—KIT—muscle cancer	6.66e-05	0.000263	CbGpPWpGaD
Afatinib—LCK—Disease—ENO2—muscle cancer	6.59e-05	0.000261	CbGpPWpGaD
Afatinib—ERBB2—Disease—KIT—muscle cancer	6.49e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CNR1—muscle cancer	6.49e-05	0.000257	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IGF2—muscle cancer	6.48e-05	0.000256	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—VEGFA—muscle cancer	6.48e-05	0.000256	CbGpPWpGaD
Afatinib—ERBB4—Disease—KIT—muscle cancer	6.4e-05	0.000253	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.39e-05	0.000253	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IGF2—muscle cancer	6.39e-05	0.000253	CbGpPWpGaD
Afatinib—EGFR—Disease—HMGA1—muscle cancer	6.22e-05	0.000246	CbGpPWpGaD
Afatinib—EGFR—Immune System—FOXO4—muscle cancer	6.04e-05	0.000239	CbGpPWpGaD
Afatinib—LCK—Disease—HMGA1—muscle cancer	5.99e-05	0.000237	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FOXO1—muscle cancer	5.97e-05	0.000236	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FOXO1—muscle cancer	5.88e-05	0.000232	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MED12—muscle cancer	5.87e-05	0.000232	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FOXO4—muscle cancer	5.84e-05	0.000231	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KIT—muscle cancer	5.84e-05	0.000231	CbGpPWpGaD
Afatinib—LCK—Immune System—FOXO4—muscle cancer	5.82e-05	0.00023	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CNR1—muscle cancer	5.73e-05	0.000227	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KIT—muscle cancer	5.63e-05	0.000222	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.62e-05	0.000222	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—FH—muscle cancer	5.61e-05	0.000222	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KIT—muscle cancer	5.61e-05	0.000222	CbGpPWpGaD
Afatinib—EGFR—Disease—FOXO4—muscle cancer	5.58e-05	0.000221	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—VEGFA—muscle cancer	5.54e-05	0.000219	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MDM2—muscle cancer	5.54e-05	0.000219	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MDM2—muscle cancer	5.46e-05	0.000216	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.42e-05	0.000214	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KIT—muscle cancer	5.4e-05	0.000214	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MDM2—muscle cancer	5.38e-05	0.000213	CbGpPWpGaD
Afatinib—LCK—Disease—FOXO4—muscle cancer	5.38e-05	0.000213	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ENO2—muscle cancer	5.35e-05	0.000212	CbGpPWpGaD
Afatinib—BLK—Immune System—MDM2—muscle cancer	5.25e-05	0.000208	CbGpPWpGaD
Afatinib—ABL1—Immune System—FOXO1—muscle cancer	5.22e-05	0.000206	CbGpPWpGaD
Afatinib—ERBB2—Disease—MDM2—muscle cancer	5.11e-05	0.000202	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KIT—muscle cancer	5.08e-05	0.000201	CbGpPWpGaD
Afatinib—ERBB4—Disease—MDM2—muscle cancer	5.04e-05	0.000199	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—muscle cancer	4.93e-05	0.000195	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—muscle cancer	4.86e-05	0.000192	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF2—muscle cancer	4.69e-05	0.000185	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—VEGFA—muscle cancer	4.63e-05	0.000183	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MDM2—muscle cancer	4.6e-05	0.000182	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KIT—muscle cancer	4.55e-05	0.00018	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTCH1—muscle cancer	4.54e-05	0.00018	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—VEGFA—muscle cancer	4.54e-05	0.000179	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KIT—muscle cancer	4.48e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—Immune System—FOXO1—muscle cancer	4.46e-05	0.000176	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MDM2—muscle cancer	4.43e-05	0.000175	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—MDM2—muscle cancer	4.41e-05	0.000175	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTCH1—muscle cancer	4.38e-05	0.000173	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FOXO1—muscle cancer	4.31e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Immune System—FOXO1—muscle cancer	4.3e-05	0.00017	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.27e-05	0.000169	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—MDM2—muscle cancer	4.25e-05	0.000168	CbGpPWpGaD
Afatinib—EGFR—Disease—FOXO1—muscle cancer	4.12e-05	0.000163	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MDM2—muscle cancer	4e-05	0.000158	CbGpPWpGaD
Afatinib—ABL1—Immune System—KIT—muscle cancer	3.98e-05	0.000157	CbGpPWpGaD
Afatinib—LCK—Disease—FOXO1—muscle cancer	3.97e-05	0.000157	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—muscle cancer	3.95e-05	0.000156	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FOXO4—muscle cancer	3.91e-05	0.000154	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CNR1—muscle cancer	3.83e-05	0.000152	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FOXO4—muscle cancer	3.76e-05	0.000149	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—muscle cancer	3.74e-05	0.000148	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CNR1—muscle cancer	3.69e-05	0.000146	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MDM2—muscle cancer	3.58e-05	0.000142	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MDM2—muscle cancer	3.53e-05	0.000139	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—muscle cancer	3.43e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Immune System—KIT—muscle cancer	3.4e-05	0.000134	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KIT—muscle cancer	3.29e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Immune System—KIT—muscle cancer	3.28e-05	0.00013	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.22e-05	0.000127	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MED12—muscle cancer	3.17e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Disease—KIT—muscle cancer	3.14e-05	0.000124	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF2—muscle cancer	3.13e-05	0.000124	CbGpPWpGaD
Afatinib—ABL1—Immune System—MDM2—muscle cancer	3.13e-05	0.000124	CbGpPWpGaD
Afatinib—LCK—Disease—KIT—muscle cancer	3.02e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF2—muscle cancer	3.02e-05	0.000119	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—muscle cancer	2.89e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FOXO1—muscle cancer	2.88e-05	0.000114	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—muscle cancer	2.82e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FOXO1—muscle cancer	2.78e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—muscle cancer	2.72e-05	0.000108	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—muscle cancer	2.68e-05	0.000106	CbGpPWpGaD
Afatinib—EGFR—Immune System—MDM2—muscle cancer	2.68e-05	0.000106	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MDM2—muscle cancer	2.59e-05	0.000102	CbGpPWpGaD
Afatinib—LCK—Immune System—MDM2—muscle cancer	2.58e-05	0.000102	CbGpPWpGaD
Afatinib—EGFR—Disease—MDM2—muscle cancer	2.47e-05	9.77e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—muscle cancer	2.38e-05	9.42e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—muscle cancer	2.38e-05	9.42e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—muscle cancer	2.3e-05	9.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—muscle cancer	2.2e-05	8.69e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—muscle cancer	2.12e-05	8.38e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—muscle cancer	2.05e-05	8.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—muscle cancer	2.02e-05	8e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—muscle cancer	1.97e-05	7.77e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—muscle cancer	1.86e-05	7.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—muscle cancer	1.73e-05	6.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—muscle cancer	1.67e-05	6.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—muscle cancer	1.49e-05	5.87e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—muscle cancer	1.31e-05	5.2e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—muscle cancer	1.27e-05	5.01e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—muscle cancer	1.01e-05	3.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—muscle cancer	9.93e-06	3.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—muscle cancer	9.57e-06	3.78e-05	CbGpPWpGaD
